On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize dengue as a systemic viral infection caused by four distinct serotypes (DENV-1, 2, 3, and 4), where DENV-2 is frequently associated with the highest virulence and risk of severe outbreaks.
- •Understand the transmission cycle involving female Aedes mosquitoes, which acquire the virus from viremic humans and can also transmit the virus vertically to their larvae, allowing environmental persistence during dry seasons.
- •Identify the primary risk factor for severe disease as secondary infection with a different serotype; this triggers antibody-dependent enhancement (ADE), where non-neutralizing antibodies facilitate viral entry into macrophages, causing a massive cytokine release.
- •Note the expanding geographic range of the vectors, with Aedes albopictus facilitating transmission in temperate regions like Southern Europe, while Aedes aegypti remains the dominant urban vector in tropical hyperendemic zones.
- •Consider the impact of comorbidities such as , , and , which significantly increase the risk of symptomatic presentation and progression to severe organ involvement.
Evaluation
- •Suspect dengue in any patient with acute high-grade fever (≥38°C) who has lived in or traveled to an endemic region (e.g., Southeast Asia, Puerto Rico, Mexico) within the last 14 days.
- •Ask about the classic triad of "breakbone fever": severe frontal headache, retro-orbital pain, and intense myalgias or arthralgias, often following a biphasic or "saddleback" fever pattern.
- •Examine the skin for the pathognomonic "isles of white in a sea of red" rash—a confluent erythematous exanthema with small circular areas of skin sparing—and check for petechiae on the extremities.
- •Perform the Tourniquet Test (TT) to assess capillary fragility: inflate a blood pressure cuff to the mean arterial pressure [(Systolic + Diastolic) / 2] for 5 minutes; a count of ≥10–20 petechiae per square inch on the ventral forearm is positive.
- •Monitor for "Warning Signs" during the transition from the febrile to the critical phase (typically days 3–7), including abdominal pain or tenderness, persistent vomiting, mucosal bleeding, and lethargy.
- •Order a (CBC) daily to track the characteristic progression of leukopenia (WBC <5,000 cells/mm³), followed by a rapid drop in platelet count and a rising hematocrit indicating plasma leakage.
- •Obtain NS1 antigen and/or RT-PCR for definitive diagnosis if the patient presents within the first 5 days of symptom onset (the viremic phase).
- •Order IgM and IgG serology if the patient presents after day 5 of illness; note that a four-fold rise in IgG titers in paired sera is diagnostic of recent infection.
- •Utilize bedside ultrasonography to detect subclinical plasma leakage, specifically looking for gallbladder wall thickening, , and pleural effusions (often appearing first on the right side).
- •Rule out co-infections such as , , and , particularly in regions where these pathogens overlap, as co-infection can exacerbate anemia and organ dysfunction.
- •Assess for neurological complications, including cerebellar , , or signs of if the patient exhibits motor weakness or altered consciousness.
- •Monitor respiratory mechanics closely if plasma leakage is suspected; an FVC < 15 mL/kg should prompt consideration for mechanical ventilation due to massive effusions or pulmonary edema.
Management
- •Administer Acetaminophen (Paracetamol) for fever and pain control, maintaining a maximum dose of 4g/day in adults; strictly avoid Aspirin and NSAIDs (e.g., Ibuprofen) due to the risk of gastritis and platelet dysfunction.
- •Encourage aggressive oral hydration in the ambulatory setting, aiming for approximately 2 liters of fluid per day (e.g., oral rehydration salts, fruit juices) to reduce the risk of hospitalization.
- •Initiate IV fluid therapy with isotonic crystalloids (e.g., Lactated Ringer's or Normal Saline) at 5–7 mL/kg/hour for patients with warning signs who cannot maintain oral intake.
- •Manage (DSS) with an immediate IV bolus of isotonic crystalloid at 10–20 mL/kg over 15–30 minutes, followed by reassessment of hemodynamic status.
- •Consider colloid boluses (e.g., 5% albumin) in patients with refractory shock or those with massive where crystalloids may worsen extravascular fluid accumulation.
- •Monitor hematocrit every 6–12 hours during the critical phase; a rising hematocrit despite fluid resuscitation suggests ongoing plasma leakage and requires an increase in fluid rate.
- •Avoid prophylactic platelet transfusions even in cases of severe thrombocytopenia; reserve transfusions for patients with clinically significant, life-threatening hemorrhage.
- •Delay elective surgeries or delivery in pregnant patients until the critical phase has passed to minimize the risk of massive maternal hemorrhage.
- •Administer IVIG 2 g/kg as a single infusion in pediatric patients who develop -like features (e.g., coronary artery aneurysms) post-dengue.
- •Refer patients to intensive care if they exhibit severe plasma leakage leading to respiratory distress, severe organ impairment (AST/ALT ≥1000 U/L), or impaired consciousness.
- •Monitor for fluid overload during the recovery phase; as third-spaced fluid is reabsorbed, decrease IV fluids and watch for signs of pulmonary edema or heart failure.
- •Discharge patients only when they have been afebrile for 48 hours without antipyretics, show a rising platelet count, and have stable hematocrit levels with improving clinical symptoms.
- •Counsel patients on the use of the Dengvaxia vaccine only if they have laboratory-confirmed prior dengue infection, as it may increase the risk of severe disease in seronegative individuals.
Board Review — High Yield
- •Breakbone fever — Common name for dengue due to severe myalgia and arthralgia.
- •Isles of white in a sea of red — Classic description of the confluent erythematous rash with skin sparing.
- •Antibody-Dependent Enhancement (ADE) — Mechanism where secondary infection with a different serotype leads to more severe disease.
- •Tourniquet Test — Bedside marker for capillary fragility; positive if ≥10-20 petechiae per square inch.
- •Critical Phase — Occurs at the time of defervescence (fever drop), which is when plasma leakage and shock are most likely.
- •NS1 Antigen — Viral protein detectable in the blood from day 1 of symptoms, used for early rapid diagnosis.
- •Hematocrit/Platelet Divergence — A rising hematocrit with a falling platelet count is a hallmark of the critical phase.
- •Dengvaxia — Vaccine only recommended for those with evidence of prior dengue infection to prevent ADE-like reactions.
Deep Dive — Evidence Details
Etiology and Triggering Factors
- ▸Dengue is caused by four distinct serotypes (DENV-1 to DENV-4), with DENV-2 typically associated with the highest virulence and risk of severe disease.
- ▸The primary mechanism for severe dengue is Antibody-Dependent Enhancement (ADE) during secondary infection with a different serotype.
- ▸Vertical transmission in Aedes larvae allows the virus to persist in the environment without a continuous human-mosquito-human cycle.
Dengue fever is caused by infection with the dengue virus (DENV), a single-stranded, positive-sense RNA virus belonging to the genus Orthoflavivirus within the family Flaviviridae [6]D[19]D. The disease is primarily transmitted to humans through the bite of infected female mosquitoes of the genus Aedes, specifically Aedes aegypti and Aedes albopictus [3][9]D. The etiology of dengue is complex, involving the interplay of four distinct viral serotypes, specific vector biological requirements, and host immune responses that can paradoxically exacerbate disease severity through antibody-dependent enhancement (ADE) [5]D[8]D.
Virological Characteristics and Serotypes
The dengue virus exists as four antigenically and genetically distinct serotypes: DENV-1, DENV-2, DENV-3, and DENV-4 [6]D[20]D. While all four serotypes can cause the full spectrum of disease—from asymptomatic infection to severe dengue—their pathogenicity and prevalence vary significantly. DENV-2 is frequently cited as the most virulent serotype and is most commonly associated with severe clinical manifestations and large-scale outbreaks [6]D[21]D.
Recent genomic analyses have highlighted the extreme sequence diversity within these serotypes, which complicates diagnostic efforts and vaccine development [13]D. For instance, DENV-1 has been identified as a dominant circulating serotype in specific regions like Bhubaneswar, India, while DENV-2 often appears during rainy seasons, sometimes as a co-infection [17]D. In the Pacific region, specific outbreaks such as those in the Marshall Islands (2019–2021) have been driven by DENV-3 [14]D.
Vector Biology and Transmission Dynamics
The primary vectors for DENV are Aedes aegypti and Aedes albopictus. A. aegypti is highly adapted to urban environments, breeding in stagnant water in artificial containers, whereas A. albopictus is more resilient in temperate climates, facilitating the spread of dengue to previously non-endemic regions like Northern Italy and Southern Europe [11]D[16]D.
Transmission Cycle Protocol
The transmission of DENV follows a specific biological sequence within the vector and host:
- Step 1: Acquisition — A female Aedes mosquito ingests DENV during a blood meal from a viremic human host [1].
- Step 2: Extrinsic Incubation — The virus replicates within the mosquito's midgut, eventually disseminating to the salivary glands. This process is regulated by the mosquito's ecdysone receptor (EcR), which normally controls vitellogenesis but is manipulated by the virus to facilitate replication [24]D.
- Step 3: Inoculation — The infectious mosquito bites a susceptible human, injecting the virus into the bloodstream or skin [1].
- Step 4: Vertical Transmission — Evidence suggests DENV can be transmitted vertically from female mosquitoes to their larvae, allowing the virus to persist in the environment even during dry seasons or periods of low human transmission [17]D.
Host and Immunological Triggers
The most significant trigger for severe dengue is a secondary infection with a heterotypic serotype. This is mediated by Antibody-Dependent Enhancement (ADE), where non-neutralizing antibodies from a prior infection bind to the new serotype but fail to neutralize it [5]D[8]D. Instead, these antibody-virus complexes are more easily internalized by Fcγ receptor-bearing cells, such as macrophages, leading to increased viral load and a massive release of pro-inflammatory cytokines [5]D[22]D.
Molecular Mechanisms
DENV manipulates host cellular machinery to ensure survival. It specifically targets host kinase-driven phosphorylation pathways to control pathogenesis [21]D. Furthermore, cross-reactive immune responses have been observed in patients with prior exposure to other flaviviruses or even SARS-CoV-2, which may influence clinical outcomes through immune crosstalk and cytokine amplification [8]D.
Environmental and Anthropogenic Factors
The expansion of dengue is heavily influenced by ecological and social triggers:
- Climate Change: Rising global temperatures and altered rainfall patterns have expanded the geographic range of Aedes mosquitoes into temperate zones [9]D[11]D.
- Urbanization and Sanitation: Poor environmental sanitation and inadequate water storage practices provide ample breeding sites for vectors, particularly in hyperendemic regions like Mexico and Bangladesh [3][12]D[14]D.
- Human Mobility: Increased international travel and migration facilitate the introduction of DENV into new areas, leading to autochthonous (local) transmission clusters in regions like Spain and Iran [9]D[11]D.
Rare and Emerging Etiological Factors
While mosquito-borne transmission is the rule, other routes and triggers are emerging:
- Iatrogenic Transmission: There is a recognized risk of transmission through blood and organ donations, necessitating enhanced screening during outbreaks [16]D.
- Co-infections: Simultaneous infection with DENV and other arboviruses (Zika, Chikungunya) or SARS-CoV-2 can complicate the clinical picture and potentially exacerbate disease severity [8]D[15]D[25]D.
| Cause/Trigger | Category | Mechanism | Associated Subtype | Key Reference |
|---|---|---|---|---|
| DENV-2 | Viral | High virulence; manipulates host kinase pathways | DENV-2 | [6]D, [21]D |
| Secondary Infection | Immunological | Antibody-Dependent Enhancement (ADE) | Heterotypic serotypes | [5]D, [8]D |
| Aedes aegypti | Vector | Urban transmission; high anthropophilic biting | All serotypes | [3], [11]D |
| Aedes albopictus | Vector | Temperate climate adaptation; expansion into Europe | All serotypes | [11]D, [16]D |
| Vertical Transmission | Ecological | Larval infection ensures environmental persistence | DENV-1, DENV-2 | [17]D |
| Ecdysone Receptor | Molecular | Regulates viral replication in mosquito midgut | All serotypes | [24]D |
| SARS-CoV-2 Crosstalk | Immunological | Cross-reactive antibodies and cytokine amplification | All serotypes | [8]D |
History and Physical Examination
- ▸The 'isles of white in a sea of red' rash is a highly specific physical finding for dengue, representing areas of skin sparing amidst confluent erythema.
- ▸The tourniquet test is a critical bedside maneuver to assess capillary fragility; a positive result (≥10-20 petechiae/sq inch) indicates a higher risk of hemorrhagic manifestations.
- ▸The transition from the febrile to the critical phase (around day 3-7) is the most dangerous period, where clinicians must watch for warning signs like abdominal pain and mucosal bleeding.
The clinical presentation of (DENV) infection is notoriously dynamic, evolving through distinct phases—febrile, critical, and recovery—that require meticulous serial examinations [39]D. For the clinician, the challenge lies in differentiating dengue from other tropical fevers like , , and , particularly in endemic regions or returning travelers [32]D[41]D. Early identification of warning signs during the transition between phases is the cornerstone of preventing progression to severe dengue [38]D.
Presenting Symptoms
The illness typically begins abruptly after an incubation period of approximately 4 to 7 days [37]C. The primary symptom is a high-grade fever, often ≥38°C, which may follow a "saddleback" (biphasic) pattern [26]. In the initial febrile phase (days 1–3), patients frequently report severe frontal headache, retro-orbital pain, and intense myalgias and arthralgias, earning the disease the moniker "breakbone fever" [39]D.
In urban populations, particularly among young adults aged 19–38, the presentation is often characterized by sudden onset of constitutional symptoms [29]. Clinicians should maintain a high index of suspicion for patients with recent travel to endemic areas such as Puerto Rico, Mexico, or Southeast Asia [32]D[37]C[42]D. Notably, patients with comorbid obesity are at a significantly higher risk for symptomatic presentation and severe disease progression [30]. This increased susceptibility may be linked to the chronic inflammatory state associated with obesity, which can exacerbate the microcirculatory alterations caused by the virus [34].
Physical Examination Findings
A systematic -to-toe examination is essential to identify the subtle markers of plasma leakage and capillary fragility.
Dermatological Findings
The most pathognomonic physical finding is the "isles of white in a sea of red" rash [37]C. This characteristic exanthema typically appears as a confluent erythematous rash with small, circular areas of skin sparing. It is thought to result from intense capillary dilation and may be accompanied by petechiae, particularly on the extremities [37]C.
Capillary Fragility: The Tourniquet Test
The tourniquet test (TT) is a vital bedside tool for assessing capillary fragility, especially in resource-limited settings where laboratory access is delayed [40]D.
Protocol for the Tourniquet Test:
- Step 1: Measure the patient’s blood pressure and calculate the mean arterial pressure (MAP): [(Systolic + Diastolic) / 2].
- Step 2: Inflate the blood pressure cuff to the MAP and maintain this pressure for 5 minutes.
- Step 3: Deflate the cuff and wait for the skin to return to normal color (approximately 2 minutes).
- Step 4: Count the number of petechiae within a 1-inch (2.5 cm) square on the ventral forearm.
A test is considered positive if there are ≥10–20 petechiae per square inch [40]D. While the TT has lower sensitivity than rapid diagnostic tests (RDTs) for early dengue, it remains a critical marker for potential hemorrhagic complications [40]D.
Neurological Examination
While dengue is primarily systemic, neurological complications are increasingly recognized. A thorough neurological screen should include:
- Motor/Cerebellar: Assess for cerebellar , which is the most common movement disorder post-DENV infection [33]D.
- Extrapyramidal: Monitor for or dystonia, which typically develop within 14 days of fever onset [33]D.
- Psychiatric: Screen for new-onset anxiety, depressive disorders, or sleep disturbances, as DENV infection is associated with an increased temporal risk of these conditions [31].
Respiratory and Abdominal Assessment
Abdominal palpation may reveal (liver enlargement >2 cm), a key warning sign of severe disease [39]D. In the context of the DENV-4 serotype, clinicians should specifically look for lower respiratory involvement, including cough (25.9%) and chest distress (15.0%) [45]D. Point-of-care lung ultrasound may be used to detect early pleural effusions, a sign of plasma leakage [45]D.
Phenotypic Variants
Dengue presents across a spectrum of severity, often influenced by prior infections or co-circulating pathogens like [43]D.
| Variant | Key Features | Frequency/Context |
|---|---|---|
| Dengue Fever (DF) | Fever, rash, myalgia, leukopenia. | Most common; often self-limiting [39]D. |
| Dengue Hemorrhagic Fever (DHF) | Plasma leakage, thrombocytopenia, hemorrhagic manifestations. | Requires close monitoring for shock [39]D. |
| Dengue Shock Syndrome (DSS) | Weak rapid pulse, narrow pulse pressure (<20 mmHg), hypotension. | Medical emergency; high mortality [39]D. |
| Expanded Dengue | Isolated organ involvement (e.g., encephalitis, , hepatitis). | Atypical; seen in severe cases [39]D. |
Red Flags (Warning Signs)
As the patient enters the critical phase (typically days 3–7), the clinician must monitor for "warning signs" that herald the onset of plasma leakage. These include:
- Abdominal pain or tenderness and persistent vomiting.
- Clinical fluid accumulation (pleural effusion, ).
- Mucosal bleeding (epistaxis, gingival bleeding).
- Lethargy or restlessness.
- Respiratory Compromise: If severe plasma leakage leads to massive effusions or pulmonary edema, monitoring respiratory mechanics is vital. FVC < 15 mL/kg → consider intubation for airway protection and ventilatory support.
Atypical Presentations
Clinicians should be wary of atypical features that may mask the diagnosis. In some outbreaks, pulmonary inflammatory symptoms are prominent, mimicking community-acquired pneumonia [45]D. Furthermore, co-infections with malaria can complicate the clinical picture, often resulting in more severe anemia or altered parasite clearance [41]D. The use of point-of-care thromboelastography (TEG) is emerging as a superior method to conventional platelet counts for predicting actual bleeding risk, as it assesses clot strength and fibrinolysis [35].
| Phase | Duration | Clinical Characteristics |
|---|---|---|
| Febrile | 2–7 days | High fever, headache, myalgia, 'isles of white' rash, positive tourniquet test [26][37]C[39]D. |
| Critical | 24–48 hours | Plasma leakage, rising hematocrit, thrombocytopenia, potential for shock (DSS) [39]D. |
| Recovery | 48–72 hours | Fluid reabsorption, stabilized vital signs, 'recovery rash' (intense itching) [39]D. |
Diagnosis and Workup
- ▸The diagnostic window is time-dependent: use NS1/PCR during the first 5 days and IgM/IgG after day 5.
- ▸A rising hematocrit combined with a rapid drop in platelet count is the primary laboratory indicator of the critical phase and plasma leakage.
- ▸Bedside ultrasound is the most sensitive imaging modality for detecting subclinical fluid accumulation like gallbladder wall thickening and ascites.
The diagnosis of Dengue Fever (DENV) requires a high index of clinical suspicion, particularly in endemic regions or in travelers returning from such areas [47]. Because the clinical presentation often overlaps with other tropical illnesses such as Malaria , , and , laboratory confirmation is essential for both clinical and epidemiological surveillance [41]D[46][55]D. The diagnostic approach is primarily dictated by the timing of the patient's presentation relative to the onset of symptoms, as the viral load and antibody response follow a predictable temporal pattern [60]D[69]D.
Diagnostic Criteria
Formal diagnosis follows the WHO 2009 classification, which categorizes patients based on the presence of warning signs and severity.
- Probable Dengue: Defined as a patient living in or traveling to a dengue-endemic area with fever and two of the following: nausea/vomiting, rash, aches and pains (headache, retro-orbital pain, myalgia, arthralgia), a positive tourniquet test, or leukopenia [56]D[62]D.
- Dengue with Warning Signs: Includes the above plus abdominal pain/tenderness, persistent vomiting, clinical fluid accumulation ( , pleural effusion), mucosal bleed, lethargy, liver enlargement >2 cm, or an increase in hematocrit concurrent with a rapid decrease in platelet count [60]D[62]D.
- Severe Dengue: Defined by severe plasma leakage (leading to shock or respiratory distress), severe bleeding, or severe organ involvement (AST or ALT ≥1000 U/L, impaired consciousness, or heart/organ failure) [22]D[56]D.
Laboratory Investigations
Laboratory workup is divided into virological tests (detecting the virus or its components) and serological tests (detecting the host immune response). The "diagnostic window" is critical: virological tests are most sensitive during the first 5 days of illness, while serological tests become reliable after day 5 [60]D[69]D.
- NS1 Antigen Detection: The NS1 (non-structural protein 1) is a glycoprotein secreted by DENV-infected cells. It is detectable in serum from day 1 of fever and typically persists for up to 9 days [51]D[60]D. NS1 assays are highly specific and are the preferred rapid test in the acute phase [42]D.
- Molecular Testing (RT-PCR): This is the gold standard for confirming infection and identifying the specific serotype (DENV-1 to DENV-4) [55]D[69]D. RT-PCR is most sensitive during the viremic phase (days 1–5). Viral loads are typically lower in secondary infections compared to primary infections [22]D. Newer technologies, such as RT-iiPCR and CRISPR-Cas12a systems, are being developed for rapid, field-deployable detection [63]D[69]D.
- Serology (IgM/IgG): Anti-dengue IgM antibodies typically appear by day 5 and remain detectable for 2–3 months [60]D. IgG appears shortly after IgM in primary infections but rises rapidly to high titers in secondary infections [54]D[60]D. A four-fold rise in IgG titers in paired sera is diagnostic of a recent infection.
- (CBC): This is the most vital monitoring tool. Leukopenia (WBC <5,000 cells/mm³) often precedes the critical phase. Thrombocytopenia (platelets <100,000 cells/mm³) and a rising hematocrit (indicating hemoconcentration from plasma leakage) are hallmarks of progression to severe disease [60]D[62]D. Platelet count abnormalities are the strongest predictors of severity [62]D.
- Biomarkers: Emerging research identifies elevated levels of GBP5 (associated with oxidative stress and endothelial leakage) and MMP-2 (secreted by neutrophils in response to NS1) as potential indicators of severe pathogenesis [52]D[66]D.
Imaging and Specialized Studies
Imaging is primarily used to detect evidence of plasma leakage, which may be subclinical in the early stages of the critical phase.
- Ultrasonography: This is the modality of choice for detecting early plasma leakage. Key findings include gallbladder wall thickening, ascites, and pleural effusions [50]C[60]D. In patients with co-morbidities like , ultrasound or CT may reveal splenomegaly or splenic infarction triggered by the infection [50]C.
- Chest X-ray: May be used to identify pleural effusions, typically appearing first on the right side.
- Electrodiagnostic Studies: While not routine for dengue, these are indicated if neurological complications arise. In cases of post-dengue , nerve conduction studies (NCS) may show reduced conduction velocity, prolonged distal latencies, and absent or delayed F-waves, reflecting acute inflammatory demyelinating polyradiculoneuropathy.
Diagnostic Algorithm
- Step 1: Clinical Screening: Evaluate for fever and dengue-specific symptoms (rash, retro-orbital pain). Assess for "warning signs" [62]D.
- Step 2: Initial Bloods: Order a CBC with differential. Look for leukopenia and baseline hematocrit [60]D.
- Step 3: Acute Phase Testing (Days 1–5): Order NS1 antigen and/or RT-PCR. If positive, dengue is confirmed [51]D[69]D.
- Step 4: Convalescent Phase Testing (>Day 5): If the patient presents late or acute tests were negative but suspicion remains high, order IgM/IgG ELISA [60]D.
- Step 5: Severity Monitoring: If warning signs are present, perform serial CBCs (every 6–12 hours) and bedside ultrasound to monitor for plasma leakage [62]D.
| Test | Target | Optimal Timing | Sensitivity | Specificity |
|---|---|---|---|---|
| RT-PCR | Viral RNA | Days 1–5 | High (>90%) | Very High (~100%) |
| NS1 Antigen | Viral Protein | Days 1–7 | Moderate-High | High [42]D[51]D |
| IgM ELISA | Host Antibody | >Day 5 | High (after day 7) | Moderate (cross-reacts) |
| IgG ELISA | Host Antibody | >Day 7 | High (secondary) | Low (cross-reacts) [54]D |
| CBC | Platelets/Hct | Daily | N/A | Predicts Severity [62]D |
Special Populations
- ▸Dengue in pregnancy significantly increases the risk of miscarriage (OR 3.51) and preterm birth (OR 1.71) through placental signaling disruption.
- ▸Pediatric oncology patients, especially those with B-ALL, face a high risk of severe dengue (21.7%) and may present with febrile neutropenia.
- ▸Chronic Kidney Disease (CKD) is a major determinant of dengue-related hospitalization and mortality in adult populations.
of requires significant modification when treating vulnerable groups, as physiological changes and comorbidities can mask early warning signs of capillary leak or exacerbate the viral impact on organ systems. In these populations, the transition from the febrile to the critical phase may be more abrupt or clinically occult.
Pregnancy and Neonatal Considerations
Pregnant women represent a high-risk group due to the physiological expansion of plasma volume, which can mask the hemoconcentration typically used to identify the onset of the critical phase. Dengue infection during pregnancy is associated with a significant increase in adverse maternal and fetal outcomes [46][71]. An umbrella review of meta-analyses indicates that maternal dengue infection increases the risk of miscarriage (OR 3.51), preterm birth (OR 1.71), and low birth weight (OR 1.41) [46].
Clinical presentation in pregnancy often includes fever (96%), headache (67%), and abdominal pain (57%) [77]D. Pregnant patients are significantly more likely to develop warning signs and require hospitalization compared to non-pregnant counterparts [75]. The risk of vertical transmission is a critical concern; the virus can cross the placental barrier by disrupting signaling pathways such as JAK/STAT and mTOR, and by evading the immune response of Hofbauer cells [73]D.
Protocol for Management in Pregnancy:
- Initial Assessment: Perform daily monitoring of hematocrit and platelet counts. A rise in hematocrit may be blunted by the baseline anemia of pregnancy.
- Fetal Surveillance: Conduct regular non-stress tests (NST) or biophysical profiles (BPP) to assess for fetal distress, particularly if the mother enters the critical phase.
- Fluid Titration: Use isotonic crystalloids (e.g., Lactated Ringer's) cautiously. Over-resuscitation can lead to pulmonary edema more rapidly in pregnant women due to decreased oncotic pressure.
- Delivery Planning: If possible, delay delivery until the critical phase has passed to minimize the risk of massive maternal hemorrhage during labor or surgical procedures [71].
Pediatric and Adolescent Populations
Children and adolescents bear a disproportionate burden of dengue, with high incidence proportions across Asia, Africa, and the Americas [70]. In pediatric patients, the differential diagnosis must remain broad, particularly in malaria-endemic regions where co-infection is common and can complicate the clinical picture [41]D.
Unique complications in children include an association with (KD). Infants presenting with prolonged fever and features of incomplete KD (e.g., coronary artery aneurysms) following a dengue diagnosis require prompt intervention with IVIG 2 g/kg as a single infusion to prevent long-term cardiac sequelae [79]C. Furthermore, pediatric patients with underlying malignancies, particularly B-cell acute lymphoblastic leukemia (B-ALL), are at high risk for severe disease. In this cohort, 21.7% of patients may develop severe dengue, often presenting as febrile neutropenia [78].
Geriatric Patients and Chronic Comorbidities
In the elderly, the risk of dengue-related mortality increases with age (adj. OR 1.03 per year) [76]. This population often has a higher prevalence of chronic comorbidities that impair the immune response and complicate fluid management. Chronic Kidney Disease (CKD) is a particularly potent risk factor; patients with CKD have significantly higher rates of hospitalization and adverse clinical outcomes following dengue infection [83]D.
Socioeconomic factors also play a critical role in outcomes for this population. Individuals in lower socioeconomic brackets or those with limited access to clean water management are at a higher risk of both infection and death [72][80]D. Environmental factors, such as exposure to wildfire smoke (PM2.5), have also been linked to increased dengue-related hospitalizations, potentially by exacerbating underlying respiratory or cardiovascular frailty [85]D.
Immunocompromised Populations
Patients with primary or secondary immunodeficiencies, including those undergoing chemotherapy, require vigilant monitoring. In pediatric oncology centers, dengue should be considered in the differential for any febrile patient, even in the absence of classic warning signs [78]. These patients may not mount a typical inflammatory response, leading to delayed diagnosis. Management focuses on aggressive supportive care and the avoidance of nephrotoxic or myelosuppressive agents during the acute viral phase.
| Outcome | Odds Ratio (OR) | Evidence Level |
|---|---|---|
| Miscarriage | 3.51 | 2a [46] |
| Preterm Birth | 1.71 | 2a [46] |
| Low Birth Weight | 1.41 | 2a [46] |
| Stillbirth | Increased Risk | 2a [71] |
| Population | Severe Dengue Rate | Key Consideration |
|---|---|---|
| General Pediatric | Varies by region | High seroprevalence with age [70] |
| Pediatric Oncology (B-ALL) | 21.7% | Often presents as febrile neutropenia [78] |
| Infants | Rare | Potential trigger for Kawasaki Disease [79]C |
Guidelines and Resources
- ▸The 2009 WHO classification (Dengue +/- Warning Signs) is the current standard for clinical triage, replacing the 1997 DHF/DSS categories.
- ▸NAAT is the gold standard for diagnosis within the first 7 days, as IgM testing is frequently confounded by cross-reactivity with Zika virus.
- ▸Oral hydration of approximately 2 liters per day is a critical primary care intervention to prevent hospitalization.
The clinical and classification of dengue have undergone significant evolution to improve triage and reduce mortality. Current global standards are primarily driven by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), focusing on early recognition of warning signs and the differentiation of dengue from other flaviviruses like Zika [87][92].
The WHO Classification Shift (1997 vs. 2009)
The most significant change in dengue guidelines was the transition from the 1997 classification (Dengue Fever, Dengue Hemorrhagic Fever, and Dengue Shock Syndrome) to the 2009 revised classification [91][92]. The 1997 criteria were often criticized for being too rigid, requiring specific laboratory evidence of plasma leakage that was not always available in resource-limited settings [92]. The 2009 classification focuses on clinical utility and triage, dividing cases into Dengue without Warning Signs, Dengue with Warning Signs, and Severe Dengue [91][93].
Retrospective studies of over 30,000 patients have shown that while the 2009 criteria are more sensitive for identifying severe cases, clinical signs and symptoms in the early stages remain poorly correlated with final disease severity, necessitating close monitoring of all patients [91]. Fever remains the core symptom, though its absence does not exclude the risk of progression to severe disease [93].
Diagnostic Guidelines and Flavivirus Differentiation
In regions where dengue and co-circulate, diagnostic clarity is essential. The 2019 CDC/MMWR guidelines emphasize that Nucleic Acid Amplification Tests (NAATs) are the preferred diagnostic method during the first 7 days of symptom onset [87].
Diagnostic Protocol (CDC 2019):
- Step 1: Perform NAAT on serum and urine samples collected within 7 days of illness onset [87].
- Step 2: If NAAT is negative, perform IgM antibody testing.
- Step 3: Interpret IgM results with caution due to cross-reactivity between dengue and Zika viruses. If IgM is positive for either, a Plaque Reduction Neutralization Test (PRNT) may be required for definitive serotype identification, though this is often limited to reference laboratories [87].
Management and Fluid Resuscitation Protocols
Guidelines emphasize that aggressive oral hydration in the ambulatory setting can significantly reduce the risk of hospitalization [94]. Observational data suggest that patients consuming approximately 2 liters (average 1863–1944 mL) of fluid per day during the febrile phase have better outcomes [94].
For patients progressing to (DSS), the WHO recommends a standardized fluid resuscitation protocol. However, clinical evidence suggests nuances based on the patient's physiological state:
Fluid Resuscitation Protocol:
- Step 1: Initiate isotonic crystalloids (e.g., Lactated Ringer's) at 5–7 mL/kg/hour for patients with warning signs [95]C.
- Step 2: For patients in shock, provide a bolus of 10–20 mL/kg over 15–30 minutes [95]C.
- Step 3: Evaluate for third-space fluid loss. While WHO guidelines prioritize crystalloids, evidence suggests that colloid boluses may be superior in patients with significant or pleural effusions to prevent further fluid accumulation in the extravascular space [95]C.
Surveillance and Vaccination Standards
Effective dengue control requires integrated surveillance systems that track mosquito density and clinical cases [88]. The Asia-Pacific and Americas Dengue Prevention Boards advocate for "active" surveillance, where laboratories report confirmed cases directly to public health authorities to trigger vector control measures [88].
Regarding immunization, the 2018/2019 updates from regional bodies like the Argentine Society of Pediatrics highlight the complexity of the dengue vaccine (Dengvaxia). It is generally recommended only for individuals with confirmed prior dengue infection to avoid the risk of severe disease in seronegative individuals upon their first natural infection [89].
Clinical Prediction and Severity Markers
Recent meta-analyses have identified key predictors during the febrile phase that increase the risk of progression to severe disease. These include persistent vomiting, mucosal bleeding, and liver enlargement >2 cm [90]. Emerging research also points to biological markers such as elevated soluble HLA-G (sHLA-G) levels, which are significantly higher in patients who develop severe dengue compared to those with uncomplicated dengue fever [96]D. Cardiac involvement, including ECG changes and elevated troponin, occurs in up to 35% of hospitalized patients and should be monitored according to WHO guidelines [100]D.
| Organization | Year | Key Recommendations |
|---|---|---|
| WHO | 2009 | Established the revised classification (Dengue +/- Warning Signs, Severe Dengue) to improve clinical management [92]. |
| CDC / MMWR | 2019 | Prioritizes NAAT for diagnosis; provides specific algorithms for differentiating Dengue from Zika [87]. |
| Asia-Pacific/Americas Boards | 2010 | Defined best practices for integrated laboratory and mosquito surveillance [88]. |
| Argentine Soc. of Pediatrics | 2019 | Updated vaccine recommendations, emphasizing serostatus screening before vaccination [89]. |
| Consensus Group (Delphi) | 2018 | Standardized clinical endpoints for use in dengue interventional trials to ensure data comparability [101]D. |
References
- [1]
Chhabra S, Chia PY, Leo YS et al.. “A systematic review of dengue controlled human infection studies: safety, viral kinetics and immunology.” PLoS neglected tropical diseases (2026). PMID: 41818269 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [2]
Lim JT, Chong CS, Chang CC et al.. “Dengue Suppression by Male Wolbachia-Infected Mosquitoes.” The New England journal of medicine (2026). PMID: 41671481 ↗
L1bRCTCited in: Etiology and Triggering Factors, Special Populations - [3]
Kamal MM, Tsheten T, Haque R et al.. “Epidemiological Characteristics of Dengue Infection in Bangladesh: A Systematic Review.” International journal of environmental research and public health (2026). PMID: 41752317 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [4]
Mandaric S, Friberg H, Gottardo R et al.. “Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trial.” Vaccine (2026). PMID: 41722532 ↗
L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors - [5]
Ma M, Ye P, Pan J et al.. “Research progress of dengue virus T cell epitope mediated cellular immunity in avoiding ADE.” Frontiers in immunology (2026). PMID: 41993171 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [6]
Zeng R, Wu T, Zheng K et al.. “Advances in anti-dengue virus properties of Traditional Chinese Medicines.” Frontiers in microbiology (2026). PMID: 41889646 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [7]
Klingelhöfer D, Braun M, Kramer IM et al.. “Characteristics, Motivation, and Challenges of Global Research on Dengue Vaccination.” Reviews in medical virology (2026). PMID: 41766108 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [8]
Parra-González M, Nájera-Maldonado L, Peralta-Cuevas E et al.. “Dengue-SARS-CoV-2 interactions: immune crosstalk, variant emergence, and clinical outcomes.” Frontiers in immunology (2026). PMID: 41727479 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [9]
Shoushtari M, Bakhshi H, Salehi-Vaziri M et al.. “Distribution of Aedes aegypti and Aedes albopictus, and the current situation of dengue fever and chikungunya in Iran and neighboring countries: a review study.” PLoS neglected tropical diseases (2026). PMID: 41671227 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [10]
Tiley K, Yakob L, O'Reilly K et al.. “Mathematical modelling of Wolbachia replacement in Aedes aegypti for dengue control: a scoping review.” Proceedings. Biological sciences (2026). PMID: 41667103 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [11]
Bononad Brugger M, Valero MA, Morales-Suárez-Varela M. “Autochthonous transmission of dengue in Europe, with special attention to the Spanish context.” Epidemiology and infection (2026). PMID: 41755671 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [12]
Cremades R, Sandoval-Pinto E, Ortega-Prieto AM et al.. “Epidemiological Characteristics of Dengue Disease in Mexico (2014-2025): A Descriptive Analysis of a Hyperendemic Country.” Pathogens (Basel, Switzerland) (2026). PMID: 41754441 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [13]
Nandakumar A, Mishra D, Shendre A et al.. “Genomic diversity analysis enables development of pan-Dengue Toehold RNA sensors.” PLoS neglected tropical diseases (2026). PMID: 41990017 ↗
L5OTHERCited in: Etiology and Triggering Factors - [14]
León TM, McCready J, Chutaro E et al.. “Outbreak of Dengue Virus Serotype 3, Republic of the Marshall Islands, 2019-2021.” Emerging infectious diseases (2026). PMID: 41986995 ↗
L5OTHERCited in: Etiology and Triggering Factors - [15]
de Barros ENC, de Almeida Roediger M, Jackson ML et al.. “Dengue Incidence, Seroprevalence, and Expansion Factors from Active Surveillance, Brazil, 2016-2021.” Emerging infectious diseases (2026). PMID: 41986958 ↗
L5OTHERCited in: Etiology and Triggering Factors - [16]
Singh J, Lazzarotto T, Merakou C et al.. “Autochthonous dengue outbreak in Northern Italy, September 2024: epidemiological, microbiological, entomological investigation and public health response.” Travel medicine and infectious disease (2026). PMID: 41985827 ↗
L5OTHERCited in: Etiology and Triggering Factors - [17]
Pal A, Priyadarsini S, Sabat J et al.. “Detection of dengue virus serotypes in Aedes larvae: a multi-location study from Bhubaneswar, India, suggestive of vertical transmission.” Virology journal (2026). PMID: 41965806 ↗
L5OTHERCited in: Etiology and Triggering Factors - [18]
Ke Y, Wei H, Luo C et al.. “Dengue transmission dynamics in China's border regions adjacent to Myanmar.” Infectious diseases of poverty (2026). PMID: 41947237 ↗
L5OTHERCited in: Etiology and Triggering Factors - [19]
Bahr LE, Rothman AL, Barrett ADT et al.. “Addressing the elephant in the room: Proceedings of the third annual Dengue Endgame Summit.” PLoS neglected tropical diseases (2026). PMID: 41920817 ↗
L5OTHERCited in: Etiology and Triggering Factors - [20]
Gajdov V, Prosic I, Kavran M et al.. “Alignment-Free Machine Learning Serotype Classification of the Dengue Virus.” Viruses (2026). PMID: 41902188 ↗
L5OTHERCited in: Etiology and Triggering Factors, Diagnosis and Workup - [21]
Jabbar AA, Shaji V, Anil A et al.. “Phosphoproteome-Entailed Kinase-Substrate Landscape of Human-DENV-2 Interaction.” International journal of molecular sciences (2026). PMID: 41898579 ↗
L5OTHERCited in: Etiology and Triggering Factors - [22]
Alagarasu K, Gurav YK, Pulinchani A et al.. “Association of Viraemic Phase Viral Load, Antibody Responses, and Immune Biomarkers With Severe Dengue.” Journal of medical virology (2026). PMID: 41891425 ↗
L5OTHERCited in: Etiology and Triggering Factors, Diagnosis and Workup - [23]
Balasubramani K, Hussain SSA, Sawant SA et al.. “Dengue transmission dynamics in an urban setting in western India.” PLoS neglected tropical diseases (2026). PMID: 41871106 ↗
L5OTHERCited in: Etiology and Triggering Factors - [24]
Weng SC, Lin YS, Tsao PN et al.. “Dual functions of the Aedes aegypti ecdysone receptor in dengue virus replication and reproduction control.” Parasites & vectors (2026). PMID: 41866575 ↗
L5OTHERCited in: Etiology and Triggering Factors - [25]
Matulis GA, Smith HP, Hall G et al.. “Characterization of arbovirus infections in patients within Haiti by screening discarded malaria rapid diagnostic test cassettes.” PLoS neglected tropical diseases (2026). PMID: 41860982 ↗
L5OTHERCited in: Etiology and Triggering Factors - [26]
Pfaar H, López-Medina E, Escudero I et al.. “Operational challenges and lessons learned from conducting febrile surveillance in a long-term randomized dengue vaccine trial in Latin America and Asia-Pacific.” Travel medicine and infectious disease (2025). PMID: 40120920 ↗
L1bRCTCited in: History and Physical Examination - [27]
Minh Nguyen N, Thi Hoai Tam D, Quang Chanh H et al.. “Safety and tolerability of metformin in overweight and obese patients with dengue: An open-label clinical trial (MeDO).” PLoS neglected tropical diseases (2025). PMID: 40591696 ↗
L2bTRIAL_NONRANDOMCited in: History and Physical Examination - [28]
Chitrapady S, Rajendran R, K H et al.. “Machine-learning-based artificial intelligence tools for the diagnosis of tropical fevers: a systematic review and meta-analysis protocol of diagnostic test accuracy.” BMJ open (2025). PMID: 40854843 ↗
L2aSR_OBSCited in: History and Physical Examination - [29]
Yosef DK, Ismail AS, Awil BS et al.. “Epidemiology of dengue fever in Somaliland: clinical features, and serological patterns from a retrospective study.” BMC infectious diseases (2025). PMID: 39910527 ↗
L2bCOHORTCited in: History and Physical Examination - [30]
Mercado-Hernandez R, Myers R, Bustos Carillo FA et al.. “Obesity Is Associated With Increased Pediatric Dengue Virus Infection and Disease: A 9-Year Cohort Study in Managua, Nicaragua.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 39004909 ↗
L2bCOHORTCited in: History and Physical Examination - [31]
Shih HI, Wang YP, Chi CY et al.. “Risks of anxiety disorders, depressive disorders, and sleep disorders in patients with dengue fever: A nationwide, population-based cohort study.” PLoS neglected tropical diseases (2024). PMID: 38959212 ↗
L2bCOHORTCited in: History and Physical Examination - [32]
Blumrick C. “Severe Infections in Returning Travelers.” The Medical clinics of North America (2025). PMID: 40185556 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [33]
Rosca EC, Garg D, Perez-Lloret S et al.. “Movement Disorders after Dengue Virus Infection: A Scoping Review.” Movement disorders : official journal of the Movement Disorder Society (2025). PMID: 39921518 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [34]
Ferraz ÁAB, Vasconcelos GP, Henriques DF et al.. “Impact of Prior Dengue or Chikungunya Infection on Bariatric Surgery Outcomes: An Observational Prospective Study.” Surgical infections (2026). PMID: 40999855 ↗
L2bCOHORTCited in: History and Physical Examination - [35]
Bhat R, Gupta N, Ravindra P et al.. “Assessment of Bleeding in Acute Febrile Illness with Thrombocytopenia Using Thromboelastography and Conventional Coagulation Parameters in the Emergency Department (ABATE): A Prospective Cohort Study.” The American journal of tropical medicine and hygiene (2025). PMID: 39933188 ↗
L2bCOHORTCited in: History and Physical Examination - [36]
León-Figueroa DA, Garcia-Vasquez EA, Diaz-Torres M et al.. “Prevalence of dengue in febrile patients in Peru: A systematic review and meta-analysis.” PloS one (2025). PMID: 40526741 ↗
L2aSR_OBSCited in: History and Physical Examination - [37]
Reddy M, Curtin J. “Fever and Rash in a Traveler.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39908174 ↗
L4CASE_REPORTCited in: History and Physical Examination - [38]
Alanazi GK, Ahmed YA, Alobaisi Y. “Bridging Gaps in Dengue Management: A Review of Diagnostics, Transfusion Needs, and Public Health Challenges.” Vector borne and zoonotic diseases (Larchmont, N.Y.) (2026). PMID: 41757795 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [39]
Ulgheri FM, Bernardes BG, Lancellotti M. “Decoding Dengue: A Global Perspective, History, Role, and Challenges.” Pathogens (Basel, Switzerland) (2025). PMID: 41011854 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [40]
Baje ZE, Lawal N, Bello MB et al.. “Dengue fever diagnosis in resource-limited settings.” Epidemiology and infection (2025). PMID: 40842435 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [41]
Moutombi Ditombi BC, Fritz M, Kombila Koumavor CA et al.. “Molecular evidence of co-circulation of different dengue virus serotypes associated with malaria co-infection among febrile children in Libreville, Gabon.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41722758 ↗
L5OTHERCited in: History and Physical Examination, Diagnosis and Workup, Special Populations - [42]
Zapata-de la Cruz M, Martínez-Vega RA, Guzmán-Priego CG et al.. “Evaluating Three Rapid Tests for Dengue in Febrile Patients in a Dengue-Endemic Area.” Tropical medicine & international health : TM & IH (2026). PMID: 41601210 ↗
L5OTHERCited in: History and Physical Examination, Diagnosis and Workup - [43]
Cruz-Altamirano E, Mayoral-Chávez MA, Ramírez-Palacios LR et al.. “Pilot proteomic analysis of immune dysregulation in dengue with prior SARS-CoV-2 infection.” Frontiers in immunology (2025). PMID: 41583452 ↗
L5OTHERCited in: History and Physical Examination, Diagnosis and Workup - [44]
Chitrapady S, Rajendran R, Haritha K et al.. “Development and evaluation of a diagnostic aiding tool for differentiating tropical fevers using artificial intelligence approach: a study protocol from tertiary care hospital in South India.” BMJ open (2026). PMID: 41490850 ↗
L5OTHERCited in: History and Physical Examination, Diagnosis and Workup - [45]
Zhang B, Guo F, Wang P et al.. “A paradigm shift in DENV-4 clinical presentation: A viewpoint on pulmonary inflammatory symptoms from the 2023 Lincang outbreak.” PLoS neglected tropical diseases (2025). PMID: 41202061 ↗
L5OTHERCited in: History and Physical Examination - [46]
Fan D, Lin D, Rao J et al.. “Adverse Pregnancy Outcomes and Prevalence Associated With Arboviral Infections (Zika, Dengue, and Chikungunya): An Umbrella Review of Systematic Reviews and Meta-Analyses.” Reviews in medical virology (2026). PMID: 41840925 ↗
L2aSR_OBSCited in: Diagnosis and Workup, Special Populations - [47]
Agboli E, Jöst H, Frangoulidis D et al.. “Dengue in deployed military personnel, 1905-2024: a systematic review of incidence, diagnostics and prevention.” Journal of travel medicine (2026). PMID: 41283862 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [48]
Durbin AP, Van Wesenbeeck L, Pierce KK et al.. “Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model.” The New England journal of medicine (2025). PMID: 41297006 ↗
L1bRCTCited in: Diagnosis and Workup - [49]
Campbell AKO, Omah I, Diouf AM et al.. “Characterisation of the First Complete Dengue Genome in Sierra Leone.” Viruses (2026). PMID: 41902206 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [50]
Busaidi SA, Naabi MA, Lawati HA et al.. “Dengue fever uncovers a late diagnosis of sickle cell disease- a case report.” BMC infectious diseases (2025). PMID: 41275084 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [51]
El Kabbani S, Saleh G. “Next-Generation Diagnostic Technologies for Dengue Virus Detection: Microfluidics, Biosensing, CRISPR, and AI Approaches.” Sensors (Basel, Switzerland) (2025). PMID: 41516578 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [52]
Chakraborty S, Kasirajan A, Sunil A et al.. “Interferon Inducible Guanylate Binding Protein 5 (GBP5) and Its Association With Oxidative Stress Markers in Regulating Dengue Severity: A Clinical and In Vitro Evaluation.” Journal of medical virology (2026). PMID: 41923484 ↗
L5OTHERCited in: Diagnosis and Workup - [53]
Martins CB, David MR, Couto-Lima D et al.. “Wolbachia wMel and wAlbB strains differentially impact the vector competence of Aedes aegypti with a Brazilian genetic background for DENV-1 virus.” Parasites & vectors (2026). PMID: 41782057 ↗
L5OTHERCited in: Diagnosis and Workup - [54]
Delaporte B, Champagne M, Ayouba A et al.. “Serological signals of past dengue exposure in general practice in southern mainland France.” Journal of infection and public health (2026). PMID: 41747456 ↗
L5OTHERCited in: Diagnosis and Workup - [55]
Hauner A, Aroni-Sierra J, Merino X et al.. “Assessing the diagnostic performance of clinical, serological and molecular approaches to improve dengue case detection in the Peruvian Amazon.” PLoS neglected tropical diseases (2026). PMID: 41662405 ↗
L5OTHERCited in: Diagnosis and Workup - [56]
Anshad AR, Saravanan S, Murugesan A et al.. “Aberrant systemic acute-phase complement responses in conjunction with soluble CR1 attribute to varying grades of dengue disease severity.” Frontiers in immunology (2025). PMID: 41624861 ↗
L5OTHERCited in: Diagnosis and Workup - [57]
Segura K, Martel F, Franco MA et al.. “Virus-like Particles and Spectral Flow Cytometry for Identification of Dengue Virus-Specific B Cells in Mice and Humans.” Viruses (2025). PMID: 41600823 ↗
L5OTHERCited in: Diagnosis and Workup - [58]
Zé-Zé L, Borges V, Gouveia BR et al.. “Detection of dengue virus serotype 2 in local Aedes aegypti populations, Madeira Island, Portugal, 2025.” Parasites & vectors (2026). PMID: 41593468 ↗
L5OTHERCited in: Diagnosis and Workup - [59]
Patil R, Kavathekar A, Prabhu M et al.. “Tracking the clinico-microbiological profile and molecular characterization of dengue cases during the monsoon-season in Belagavi, Karnataka.” PLoS neglected tropical diseases (2026). PMID: 41557724 ↗
L5OTHERCited in: Diagnosis and Workup - [60]
Pereira SH, Franco-Luiz APM, Nogueira CT et al.. “Clinical, Serological, and Molecular Profile of Dengue Patients With Warning Signs During the 2024 Outbreak in Belo Horizonte, Brazil.” Journal of medical virology (2026). PMID: 41536183 ↗
L5OTHERCited in: Diagnosis and Workup - [61]
Elenga N, Thomas Boizan N, Irakoze E et al.. “Does Hydroxyurea Reduce Hospital Admissions in Patients With Both Sickle Cell Disease and Dengue Fever?” Pediatric blood & cancer (2026). PMID: 41524649 ↗
L5OTHERCited in: Diagnosis and Workup - [62]
Olarte G, Salamanca-Leguizamón C, Serrano-Coll H. “Epidemiological Profile and Clinical Determinants of Dengue Severity in a Colombian Andean Municipality.” The Yale journal of biology and medicine (2025). PMID: 41477460 ↗
L5OTHERCited in: Diagnosis and Workup - [63]
Tan C, Xing S, Xie X et al.. “Development and Application of a Rapid Field Detection Technology for DENV-2 Based on the HUDSON Nucleic Acid Extraction-Free/RT-RAA/CRISPR-Cas12a System.” Viruses (2025). PMID: 41472250 ↗
L5OTHERCited in: Diagnosis and Workup - [64]
Otero LM, Medina J, Ruiz-Valcarcel J et al.. “Monitoring Dengue Virus in Aedes aegypti to Improve Dengue Surveillance and Control in Puerto Rico.” Viruses (2025). PMID: 41472210 ↗
L5OTHERCited in: Diagnosis and Workup - [65]
Joensuu R, Olander V, Masika M et al.. “Dengue virus serotype 4 in Aedes aegypti mosquitoes in Kenya.” PLoS neglected tropical diseases (2025). PMID: 41468381 ↗
L5OTHERCited in: Diagnosis and Workup - [66]
Niranjan R, Ganesh K, Sunil A et al.. “Elucidation of neutrophils-mediated effect of MMP-2 on lung epithelial cells; implications for acute respiratory distress syndrome and severe dengue pathogenesis.” Frontiers in cellular and infection microbiology (2025). PMID: 41459161 ↗
L5OTHERCited in: Diagnosis and Workup - [67]
Limthongkul J, Attanonchai S, Yodweerapong T et al.. “A novel potent autophagy inhibitor HM-013 limits production of infectious dengue virus particles.” Virology journal (2025). PMID: 41444907 ↗
L5OTHERCited in: Diagnosis and Workup - [68]
Das S, Begum F, Ghora S et al.. “Engineered dengue virus NS1 mRNA-lipid nanoparticle induces therapeutic IgG production that lacks autoantibody activity and neutralizes NS1 entry in liver cells.” Vaccine (2026). PMID: 41442864 ↗
L5OTHERCited in: Diagnosis and Workup - [69]
Liu LT, Chen PC, Lin PC et al.. “Defining the clinical utility of dengue RT-iiPCR: stratification by days post-onset and primary vs. secondary infection during the 2023 Taiwan outbreak.” Travel medicine and infectious disease (2026). PMID: 41386401 ↗
L5OTHERCited in: Diagnosis and Workup - [70]
Nunez C, Eslick GD, Teutsch S et al.. “Global epidemiology of dengue in paediatric and adolescent populations: a systematic review and meta-analysis.” Infectious diseases (London, England) (2026). PMID: 41201140 ↗
L2aSR_OBSCited in: Special Populations - [71]
Goicochea-Ríos EDS, Otiniano NM, Rojas-Infantas LDC et al.. “Dengue infection during pregnancy and the occurrence of pathological neonatal outcome: a systematic review and meta-analysis.” F1000Research (2024). PMID: 40792237 ↗
L2aSR_OBSCited in: Special Populations - [72]
Cardim LL, Teixeira MDG, Costa MDCN et al.. “Socioeconomic markers of dengue mortality in the 100 Million Brazilian Cohort (2007-2018): A nationwide registry-based cohort study.” PLoS neglected tropical diseases (2025). PMID: 41183110 ↗
L2bCOHORTCited in: Special Populations - [73]
Mukherjee I, Ferland N, Nguyen KT et al.. “Comparative analysis of placental transmission mechanisms for Dengue and Zika viruses: outcomes and future directions.” Frontiers in immunology (2026). PMID: 41869332 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [74]
Luhm KR, Shimakura SE, Raboni SM et al.. “Dengue Vaccine Effectiveness: Results from a 6-Year Population-Based Cohort Study in Southern Brazil.” The American journal of tropical medicine and hygiene (2026). PMID: 41662753 ↗
L2bCOHORTCited in: Special Populations - [75]
Etoa Ndoko AC, Tran PL, Lafont M et al.. “Clinical and biological characteristics of dengue in pregnant women in Reunion Island: A nested case-control analysis in the EPIDENGUE cohort study.” European journal of obstetrics, gynecology, and reproductive biology (2026). PMID: 41483607 ↗
L2bCOHORTCited in: Special Populations - [76]
Mejia R, Zhan B, Uzcategui NL et al.. “Chagas and Vector-Borne Disease Exposures in an Indigenous Community in the Ecuadorian Amazon: A Retrospective Study.” The American journal of tropical medicine and hygiene (2025). PMID: 40774243 ↗
L2bCOHORTCited in: Special Populations - [77]
Nombera-Aznaran N, Guevara-Lazo D, Llontop-Silva V et al.. “Dengue Virus Infection in Pregnancy during the 2023 and 2024 Dengue Outbreaks in Peru: A Retrospective Review in a Tertiary Referral Center.” The American journal of tropical medicine and hygiene (2025). PMID: 40858121 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [78]
Rajan Radha R, Rajeswari B, Varikkattu Rajendran P et al.. “Dengue Infection in Pediatric Patients With Malignancies: A Single-center Retrospective Study.” Journal of pediatric hematology/oncology (2026). PMID: 41467899 ↗
L2bCOHORTCited in: Special Populations - [79]
Govardhan C, Narayanaswamy B, Ragavaiah Naidu P et al.. “Concomitant Dengue fever and Kawasaki disease in an infant: case report and review of the literature.” Paediatrics and international child health (2025). PMID: 41020614 ↗
L4CASE_REPORTCited in: Special Populations - [80]
Batheja D, Samria D, Wimberly MC et al.. “Socioeconomic and household water management determinants of malaria and other vector-borne disease prevention in Urban Gujarat, India.” Malaria journal (2026). PMID: 41703587 ↗
L5OTHERCited in: Special Populations - [81]
Velayutham R, Kalra S, Yadav S et al.. “Trends in dengue incidence and disease burden in South Asia with special reference to India: Insights from the global burden of disease data, 1990-2021.” Journal of infection and public health (2026). PMID: 41666533 ↗
L5OTHERCited in: Special Populations - [82]
Camprubí-Ferrer D, Thayer MB, Madewell ZJ et al.. “Economic burden of dengue in Puerto Rico, 2010-2023.” Infectious diseases of poverty (2026). PMID: 41588438 ↗
L5OTHERCited in: Special Populations - [83]
de Barros Almeida RAM, Kurozawa LL, de Almeida GB et al.. “Adverse dengue outcomes in patients with chronic kidney disease: A population-based analysis of 5.8 million individuals from Brazil.” PLoS neglected tropical diseases (2026). PMID: 41557722 ↗
L5OTHERCited in: Special Populations - [84]
Rahul A, Vijayalaksmi G, Vijayakumar B et al.. “Epidemiological and clinical trends in pediatric dengue: A six-year retrospective hospital-based study on pre-vs pandemic patterns in Puducherry, India.” Journal of infection and public health (2026). PMID: 41483530 ↗
L5OTHERCited in: Special Populations - [85]
Mahendran R, Zhang L, Xu R et al.. “Wildfire smoke and dengue burden in Brazil: Evidence from a nationwide study.” Environmental pollution (Barking, Essex : 1987) (2026). PMID: 41360345 ↗
L5OTHERCited in: Special Populations - [86]
Torres-Hernández D, Grubaugh ND, Murillo-Ortiz MA et al.. “Epidemiology and severity risk factors of dengue virus infection during the 2023-2024 outbreak in Colombia.” PLoS neglected tropical diseases (2025). PMID: 41348908 ↗
L5OTHERCited in: Special Populations - [87]
Sharp TM, Fischer M, Muñoz-Jordán JL et al.. “Dengue and Zika Virus Diagnostic Testing for Patients with a Clinically Compatible Illness and Risk for Infection with Both Viruses.” MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports (2019). PMID: 31194720 ↗
L1cGUIDELINECited in: Guidelines and Resources - [88]
Beatty ME, Stone A, Fitzsimons DW et al.. “Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards.” PLoS neglected tropical diseases (2010). PMID: 21103381 ↗
L1cGUIDELINECited in: Guidelines and Resources - [89]
. “[Update on vaccines: 2018 recommendations].” Archivos argentinos de pediatria (2019). PMID: 31833342 ↗
L1cGUIDELINECited in: Guidelines and Resources - [90]
Sangkaew S, Ming D, Boonyasiri A et al.. “Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2021). PMID: 33640077 ↗
L2aSR_OBSCited in: Guidelines and Resources - [91]
da Silva NS, Undurraga EA, Verro AT et al.. “Comparison between the traditional (1997) and revised (2009) WHO classifications of dengue disease: a retrospective study of 30 670 patients.” Tropical medicine & international health : TM & IH (2018). PMID: 30282115 ↗
L2bCOHORTCited in: Guidelines and Resources - [92]
Alexander N, Balmaseda A, Coelho IC et al.. “Multicentre prospective study on dengue classification in four South-east Asian and three Latin American countries.” Tropical medicine & international health : TM & IH (2011). PMID: 21624014 ↗
L2bCOHORTCited in: Guidelines and Resources - [93]
Tukasan C, Furlan NB, Estofolete CF et al.. “Evaluation of the importance of fever with respect to dengue prognosis according to the 2009 WHO classification: a retrospective study.” BMC infectious diseases (2017). PMID: 28052760 ↗
L2bCOHORTCited in: Guidelines and Resources - [94]
Besnard O, Maillard O, Franco JM et al.. “Hydration and clinical warning signs of dengue fever in primary care: An observational prospective study.” Infectious diseases now (2023). PMID: 37054972 ↗
L2bCOHORTCited in: Guidelines and Resources - [95]
Premaratna R, Liyanaarachchi E, Weerasinghe M et al.. “Should colloid boluses be prioritized over crystalloid boluses for the management of dengue shock syndrome in the presence of ascites and pleural effusions?” BMC infectious diseases (2011). PMID: 21356095 ↗
L4CASE_REPORTCited in: Guidelines and Resources - [96]
Anh DD, The NT, Song LH et al.. “Elevated Soluble HLA-G Levels Associate With Dengue Severity in Vietnamese Patients.” Journal of medical virology (2025). PMID: 40910405 ↗
L5OTHERCited in: Guidelines and Resources - [97]
Ng CF, Lum LC, Ismail NA et al.. “Clinicians' diagnostic practice of dengue infections.” Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology (2007). PMID: 17928264 ↗
L5OTHERCited in: Guidelines and Resources - [98]
Tai AY, McGuinness SL, Robosa R et al.. “Management of dengue in Australian travellers: a retrospective multicentre analysis.” The Medical journal of Australia (2017). PMID: 28403751 ↗
L5OTHERCited in: Guidelines and Resources - [99]
Lovera D, Martinez de Cuellar C, Araya S et al.. “Clinical Characteristics and Risk Factors of Dengue Shock Syndrome in Children.” The Pediatric infectious disease journal (2016). PMID: 27455442 ↗
L5OTHERCited in: Guidelines and Resources - [100]
Shah C, Vijayaraghavan G, Kartha CC. “Spectrum of cardiac involvement in patients with dengue fever.” International journal of cardiology (2021). PMID: 32931859 ↗
L5OTHERCited in: Guidelines and Resources - [101]
Jaenisch T, Hendrickx K, Erpicum M et al.. “Development of standard clinical endpoints for use in dengue interventional trials: introduction and methodology.” BMC medical research methodology (2018). PMID: 30442099 ↗
L5OTHERCited in: Guidelines and Resources